BIOMERICA INC (BMRA) Form 10-Q — Oct 15, 2026
Biomerica's fiscal Q1 (August 31, 2026) 10-Q raises substantial doubt about the company's ability to continue as a going concern, with management stating that $2.7 million in cash is insufficient to fund operations for the next twelve months. Revenue fell 8% year over year to $1.27 million while cost of sales jumped to 92% of revenue from 69%, cutting gross profit to $103,000 from $424,000 and driving a net loss of $1.23 million ($0.37 per share). The company raised $2.2 million gross in an August private placement at $1.60 per share, boosting shares outstanding roughly 44% to 4.6 million.
Key figures
- Revenue
- 1265000
- Total Debt
- 500000
- Revenue Yoy
- -8%
- Total Assets
- 8071000
- Cash Position
- 2733000
- Shares Outstanding
- 4598968
- Gross profit
- 103000
- Working capital
- 2572000
- Accumulated deficit
- 58175000
- Msa initial target fee
- 1750000
- Replacement shelf size
- 250000000
- Gross profit prior year
- 424000
- Private placement shares
- 1393705
- Cost of sales pct revenue
- 92% vs 69% prior year
- Cms payment rate inf Foods
- 300
- Medicare orders august 2026
- 10
- Medicare orders september 2026
- 22
- Private placement gross proceeds
- 2231000
- Private placement price per share
- 1.6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.